目的 探討西黃膠囊聯(lián)合他莫昔芬治療乳腺增生癥的臨床效果。方法 選取選取2017年1月-2019年8月濮陽(yáng)市中醫(yī)醫(yī)院收治的乳腺增生癥患者102例，隨機(jī)分為對(duì)照組和治療組，每組各51例。對(duì)照組口服枸櫞酸他莫昔芬片，1片/次，2次/d。治療組在對(duì)照組基礎(chǔ)上口服西黃膠囊，4~8粒/次，2次/d。連續(xù)治療2個(gè)月為1療程。觀察兩組的臨床療效，比較兩組治療前后乳房超聲檢查指標(biāo)和相關(guān)性激素指標(biāo)的變化情況。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別是82.4%、96.1%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組乳房輸乳管內(nèi)徑、腫塊直徑及腺體層厚度均較治療前顯著降低（P<0.05）；治療后，治療組患者輸乳管內(nèi)徑、腫塊直徑及腺體層厚度均顯著小于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組雌二醇（E₂）、促卵泡成熟激素（FSH）、黃體生成激素（LH）、催乳激素（PRL）及睪酮（T）水平均較治療前顯著降低（P<0.05）；治療后，治療組性激素指標(biāo)顯著低于對(duì)照組，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 西黃膠囊聯(lián)合他莫昔芬治療乳房增生癥具有較好的臨床療效，可明顯改善患者的臨床癥狀，降低性激素水平，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical effect of xihuang capsule combined with tamoxifen in the treatment of breast hyperplasia. Methods 102 Patients with mammary hyperplasia admitted to Puyang Hospital of Traditional Chinese Medicine from January 2017 to August 2019 were randomly divided into two groups. The control group was po administered with Tamoxifen Citrate Tablets, 1 tablet/time, twice daily. The treatment group was po administered with Xihuang Capsules on the basis of the control group, 4-8 grains/time, twice daily. Continuous treatment for 2 months is a course of treatment. The clinical efficacy of the two groups was observed, and the changes of breast ultrasound examination indexes and related sex hormone indexes before and after treatment were compared. Results After treatment, the total effective rate in the control group and the treatment group was 82.4% and 96.1%, respectively, and there were differences between two groups (P<0.05). After treatment, the inner diameter of the lactiferous duct, the diameter of the mass and the thickness of the glandular layer in the treatment group were significantly lower than before treatment (P<0.05). After treatment, the inner diameter of lactiferous duct, mass diameter and glandular thickness of patients in the treatment group were significantly smaller than those in the control group, and the differences between the two groups were statistically significant (P<0.05). After treatment, levels of estradiol (E₂), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL) and testosterone (T) in both groups were significantly lower than before treatment (P<0.05). After treatment, the sex hormone indexes of the treatment group were significantly lower than those of the control group, and the difference between the two groups was statistically significant (P<0.05). Conclusion Xihuang Capsules combined with tamoxifen has better clinical efficacy in treatment of mammary hyperplasia, and can significantly improve the patient's clinical symptoms, and also can reduce the level of sex hormones, which has a certain clinical application value.

R984

河南省醫(yī)學(xué)科技攻關(guān)項(xiàng)目（201602169）